Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedLayout and formatting updates to the study record page were observed. Core study content like eligibility criteria, outcomes, and enrollment status remains unchanged.SummaryDifference0.1%

- Check41 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision tag on the page updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page shows a system revision (Revision: v3.4.2) and removal of a prior revision (v3.4.1), plus a site-wide notice about government funding status. These are administrative updates and do not modify trial content or study details; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check84 days agoChange DetectedNotice added about government funding lapse affecting data currency; page revision updated to v3.4.1.SummaryDifference0.5%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.